Senate Drug Safety Hearings Will Take Broad View Of FDA Process

The Senate Health Committee is planning a series of hearings on drug safety issues in March on topics including FDA’s drug approval process and the delayed “Critical Path” drug development initiative. It is premature to predict how drug safety controversies will impact FDA post-marketing authority, House and Senate staffers say.